Application of Ectoin Allergy Nasal Spray in Comparison to Beclomethasone Nasal Spray

Bitop AG50 enrolled

Overview

This is a comparative, open label, parallel group, non interventional study to further demonstrate the effectiveness and tolerability of Ectoin® Allergy Nasal Spray. In addition the effectiveness and safety shall be compared to a Beclomethasone nasal spray. The patient applies Ectoin® Rhinitis Nasal Spray or Beclomethasone nasal spray according to the instructions for use. The observation takes place over a period of 14 days. Response to treatment is recorded at day 7 and day 14 by the physician and in daily by the patient in a dairy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Allergic Rhinitis

Interventions

Medical Device, drug-likeOTHER

Ectoin Allergy Nasal Spray

BeclomethasoneDRUG

Beclomethasone nasal spray

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed allergic rhinitis during the observational period Exclusion Criteria: * Contra indications according to the label

Outcomes

Primary Outcomes

Change in Total Nasal Symptom Score

Time frame: Time Frame: day 1, day 7, day 14

Secondary Outcomes

Change in palatal itching score

Time frame: Day 1, 7 and 14

Efficacy and tolerability assessment by the patients and by the investigator

Time frame: day 7 and 14

Change in quality of life assessed by Rhinitis Quality of Life Questionnaire

Time frame: Day1 and Day 14

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.